findmyKOL
Clinical trialNCT01232738CompletedPhase 2Interventional

Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

SponsorYunxia Wang, MDEnrollment36Amyotrophic Lateral Sclerosis (ALS)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS. Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics and it is approved for use for patients with another disorder, the effectiveness of rasagiline for patients with ALS has not been tested.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Mcgill University

    Montreal, Quebec, Canada

United States
  • Phoenix Neurological Institute

    Phoenix, Arizona, United States

  • California Pacific Medical Center

    San Francisco, California, United States

  • University of Iowa

    Iowa City, Iowa, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, United States

  • University of Minnesota

    Minneapolis, Minnesota, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • University of Tennessee

    Memphis, Tennessee, United States

  • the Methodist Hospital System

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rasagiline →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2011
Primary completion
31 May 2013
Completion
31 May 2013
Last update posted
18 May 2018
Registered enrollment
36
Registry id
NCT01232738
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.